Prevention of chemotherapy induced nausea and vomiting: A focus on aprepitant Aprepitant Sankhala, Pandya, Sarantopoulos, Soefje, Giles & Chawla

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 12, 2009, Pages 1607-1614

  Sankhala, Kamalesh K ^a   Pandya, Devesh M ^b   Sarantopoulos, John ^a   Soefje, Scott A ^a   Giles, Francis J ^a   Chawla, Sant P ^c  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Sarcoma Oncology Center   (United States)

Author keywords

Aprepitant; Chemotherapy induced nausea and vomiting; Clinical studies; Drug interaction; Neurokinin 1 inhibitors; Pharmacokinetics; Pharmacology

Indexed keywords

APREPITANT; CARBAMAZEPINE; CASOPITANT; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DILTIAZEM; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EZLOPITANT; FOSAPREPITANT; IFOSFAMIDE; IMATINIB; IRINOTECAN; ITRACONAZOLE; KETOCONAZOLE; NAVELBINE; NEFAZODONE; NELFINAVIR; PHENYTOIN; RIFAMPICIN; RITONAVIR; TAXANE DERIVATIVE; THIOTEPA; TOLBUTAMIDE; TROLEANDOMYCIN; UNINDEXED DRUG; VINCA ALKALOID; VOFOPITANT; WARFARIN;

AGE; ANTIEMETIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; FATIGUE; HICCUP; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PROPHYLAXIS; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; TAX;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MORPHOLINES; NAUSEA; RECEPTORS, NEUROKININ-1; VOMITING;

EID: 71049138916     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903451675     Document Type: Review

References (39)

1. Osoba D, et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5(4):307-313
2. Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1987;1(8543):1198
3. De Boer-Dennert M, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76(8):1055-1061
4. Olver I, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 1996;7(9):945-952
5. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60(3):533-546
6. Hesketh PJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21(22):4112-4119
7. Poli-Bigelli S, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97(12):3090-3098
8. Chawla SP, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97(9):2290-2300
9. EMEND product information. Whitehouse Station, N.J., 08889 USA; MERCK & CO., Inc; 2006
10. Bergstrom M, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 2004;55(10):1007-1012
11. Majumdar AK, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 2006;46(3):291-300
12. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008;112(9):2080-2087
13. Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 2007;16(12):1977-1985
14. Grunberg SM, et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(6):549-558
15. Bergman AJ, et al. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet 2005;44(6):637-647
16. Sanchez RI, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004;32(11):1287-1292
17. De Jonge ME, et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005;56(4):370-378
18. Jarkowski A. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. Am J Health Syst Pharm 2008;65(23):2229-2231
19. Nygren P, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005;55(6):609-616
20. Loos WJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007;59(3):407-412
21. Depre M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61(5-6):341-346
22. Shadle CR, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004;44(3):215-223
23. Blum RA, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25(5):1407-1419
24. Shah AK, et al. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 2005;21(4):595-601
25. McCrea JB, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74(1):17-24
26. Kris MG, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24(18):2932-2947
27. Navari RM, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999;340(3):190-195
28. Campos D, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19(6):1759-1767
29. De Wit R, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21(22):4105-4111
30. Schmoll HJ, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17(6):1000-1006
31. Oechsle K, et al. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. Onkologie 2006;29(12):557-561
32. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007;12(9):1143-1150
33. Gore L, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009;52(2):242-247
34. Grunberg SM, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100(10):2261-2268
35. Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23(12):2822-2830
36. Rapoport BL, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2009
37. Herrstedt J, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104(7):1548-1555 (Pubitemid 41356171)
38. Jordan K, et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009;45(7):1184-1187
39. Lordick F, et al. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 2007;43(2):299-307